Publisher Correction | Published:

Publisher Correction: Death by inflammation: drug makers chase the master controller

Nature Biotechnology (2019) | Download Citation

Subjects

Correction to: Nature Biotechnology https://doi.org/10.1038/s41587-019-0023-4, published online 4 February 2019.

In the version of this article initially published, a GlaxoSmithKline compound referred to as GSK298559 was listed in Table 1 as a RIPK1 inhibitor in phase 1 trials for inflammatory bowel disease. The correct designation is GSK2983559; however, this compound is a RIPK2 inhibitor and thus should not have been included in the table in question. The table row has been deleted. The error has been corrected in the HTML and PDF versions of the article.

Author information

Affiliations

  1. Dublin, Ireland

    • Cormac Sheridan

Authors

  1. Search for Cormac Sheridan in:

Corresponding author

Correspondence to Cormac Sheridan.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/s41587-019-0082-6